Compass Therapeutics is re-engaging FDA on Tevesimig for biliary tract cancer and targets a BLA submission in the first half of the coming year. The company reported $163 million in cash, well into 2028.
CMPX · Compass Therapeutics, Inc.
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Key stats
- Close
- $0.68
- Open
- $0.62
- Day range
- $0.60–0.68
- 52-week closing range
- $0.61–6.69
- Average volume, 30 days
- 2.4M
- Short interest
- 40.8M · 22.6% of shares · 18.9 days
- Short volume, last session
- 41%
- Last earnings
- May 20, 2026
- Latest filing
- 10-Q · Nov 9
- Price history
- Apr 2021 to Nov 2026
Up next
Latest documents
Compass Therapeutics is pursuing FDA engagement after Tevesimig more than tripled the overall response rate and reported a 0.44 progression-free survival hazard ratio, but overall survival did not differ in intent-to-treat analysis.
Compass Therapeutics held $163 million in cash, cash equivalents and marketable securities as of September 30, 2026 and expects those resources to fund operating expenses and capital expenditure requirements into 2028.
Compass Therapeutics is preparing a tovecimig BLA for biliary tract cancer despite FDA's recommendation for an additional survival-benefit study. It reported a $27.2 million quarterly net loss, with $163 million in cash and marketable securities expected to fund operations into 2028.
On September 22, 2026, Compass Therapeutics said the FDA recommended a survival-benefit trial before a tovecimig BLA submission for previously treated, advanced biliary tract cancer; the company disputes that need and plans further FDA engagement.
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| cash and marketable securities | $163M | end of Q3 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CMPX
this stock
Compass Therapeutics, Inc.
|
$122.19M | -87.4% | -100.0% | — | 22.6% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$132.01B | +14.8% | +46.2% | 33.5 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$95.52B | +19.6% | +20.8% | 20.4 | 2.1% |
|
MRNA
Moderna, Inc.
|
$80.65B | +575.9% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$63.36B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 11, 2026
- This year
- 20
Compass Therapeutics is re-engaging FDA on Tevesimig for biliary tract cancer and targets a BLA submission in the first half of the coming year. The company reported $163 million in cash, well into 2028.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CMPX | -17.3% | -15.4% | -69.4% | -13.7% | -87.4% |
| SPY | -5.5% | -6.3% | -5.6% | -5.3% | +5.0% |
| vs SPY | -11.8% | -9.1% | -63.8% | -8.5% | -92.3% |